Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials A. ValachisN. P. PolyzosD. Mauri Review 09 January 2010 Pages: 1 - 7
Overall survival in metastatic breast cancer: always our quest but not necessarily a primary endpoint Nicholas J. Robert Invited Commentary 22 May 2010 Pages: 9 - 10
Effect of BRCA1/2 mutation on short-term and long-term breast cancer survival: a systematic review and meta-analysis Eun-Ha LeeSue K. ParkKorean Breast Cancer Society Review 08 April 2010 Pages: 11 - 25
Multicentric and multifocal versus unifocal breast cancer: is the tumor-node-metastasis classification justified? Tobias M. WeissenbacherMadeleine ZschageDarius Dian Review 08 May 2010 Pages: 27 - 34
HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment Britta WeigeltAlvin T. LoMina J. Bissell Preclinical study 22 August 2009 Pages: 35 - 43
PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis Mohammed A. AleskandaranyEmad A. RakhaAndrew R. Green Preclinical study 22 August 2009 Pages: 45 - 53
The RNA-binding protein HuR regulates GATA3 mRNA stability in human breast cancer cell lines Lauren A. LicataChristine L. HostetterJudith Clancy Keen Preclinical study 02 September 2009 Pages: 55 - 63
Evidence for a transcriptional signature of breast cancer Yumei FengXiaoqing LiXishan Hao Preclinical study 02 September 2009 Pages: 65 - 75
In primary breast cancer the mitotic activity yields similar prognostic information as the histological grade: a study with long-term follow-up P. BultP. MandersR. Holland Preclinical study 17 September 2009 Pages: 77 - 86
A dose- and time-controllable syngeneic animal model of breast cancer microcalcification Fangbing LiuPreeti MisraJohn V. Frangioni Preclinical study 17 September 2009 Pages: 87 - 94
Unfavourable clinicopathologic features and low response rate to systemic adjuvant therapy: results with regard to poor survival in young Chinese breast cancer patients Li-Chen TangWen-Jin YinZhi-Ming Shao Preclinical study 17 September 2009 Pages: 95 - 104
The complete family of epidermal growth factor receptors and their ligands are co-ordinately expressed in breast cancer Emmet McIntyreEdith BlackburnWilliam J. Gullick Preclinical study 17 September 2009 Pages: 105 - 110
Transactivation of ErbB-2 induced by tumor necrosis factor α promotes NF-κB activation and breast cancer cell proliferation Martín A. RivasMercedes TkachRoxana Schillaci Preclinical study 18 September 2009 Pages: 111 - 124
Four human breast cancer cell lines with biallelic inactivating α-catenin gene mutations Antoinette HollestelleFons ElstrodtMieke Schutte Preclinical study 18 September 2009 Pages: 125 - 133
Adoptively transferred ex vivo expanded γδ-T cells mediate in vivo antitumor activity in preclinical mouse models of breast cancer Benjamin H. BeckHyung-Gyoon KimRichard D. Lopez Preclinical study 18 September 2009 Pages: 135 - 144
Coadministration of nanosystems of short silencing RNAs targeting oestrogen receptor α and anti-oestrogen synergistically induces tumour growth inhibition in human breast cancer xenografts Céline BouclierVéronique MarsaudJack-Michel Renoir Preclinical study 22 September 2009 Pages: 145 - 158
Induction of the small heat shock protein αB-crystallin by genotoxic stress is mediated by p53 and p73 Joseph R. EvansJoshua D. BosmanVincent L. Cryns Preclinical study 24 September 2009 Pages: 159 - 168
Maintenance treatment with Pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study Emilio AlbaManuel Ruiz-BorregoMiguel Martín Clinical trial 02 April 2010 Pages: 169 - 176
Holding back the sea: the role for maintenance chemotherapy in metastatic breast cancer C. G. MurphyM. KhasrawA. D. Seidman Invited Commentary 11 May 2010 Pages: 177 - 179
Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer Valentina GuarneriDavid MilesPierFranco Conte Clinical trial 02 April 2010 Pages: 181 - 188
Osteonecrosis of the jaw and bevacizumab therapy Catherine Van Poznak Invited Commentary 13 May 2010 Pages: 189 - 191
SULT1A1 R213H polymorphism and breast cancer risk: a meta-analysis based on 8,454 cases and 11,800 controls Zhanwei WangYuanyuan FuWen-ming Chu Epidemiology 01 December 2009 Pages: 193 - 198
Dietary acrylamide intake and estrogen and progesterone receptor-defined postmenopausal breast cancer risk Grete S. PedersenJanneke G. F. HogervorstPiet A. van den Brandt Epidemiology 01 December 2009 Pages: 199 - 210
Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer Edoardo BotteriMaria Teresa SandriFranco Nolè Epidemiology 06 December 2009 Pages: 211 - 217
Information from CTC measurements for metastatic breast cancer prognosis—we should do more than selecting an “optimal cut point” T. FehmW. Sauerbrei Invited Commentary 04 February 2010 Pages: 219 - 220
No association between CYP17 T-34C polymorphism and breast cancer risk: a meta-analysis involving 58,814 subjects Lei YaoFang FangLong Yu Epidemiology 15 December 2009 Pages: 221 - 227
Dietary lignan intakes in relation to survival among women with breast cancer: the Western New York Exposures and Breast Cancer (WEB) Study Susan E. McCannLilian U. ThompsonJo L. Freudenheim Epidemiology 22 December 2009 Pages: 229 - 235
No association between CYP1B1 Val432Leu polymorphism and breast cancer risk: a meta-analysis involving 40,303 subjects Lei YaoFang FangLong Yu Epidemiology 24 December 2009 Pages: 237 - 242
The functional promoter polymorphism (−842G>C) in the PIN1 gene is associated with decreased risk of breast cancer in non-Hispanic white women 55 years and younger Chan H. HanJiachun LuLi-E Wang Epidemiology 24 December 2009 Pages: 243 - 249
Current evidence on the relationship between polymorphisms in the COX-2 gene and breast cancer risk: a meta-analysis Ke-Da YuAo-Xiang ChenZhi-Ming Shao Epidemiology 24 December 2009 Pages: 251 - 257
Lack of association between CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis of 22,090 cases and 28,498 controls Chen MaoXi-Wen WangQing Chen Epidemiology 24 December 2009 Pages: 259 - 265
TNFα −308 G/A polymorphism is associated with breast cancer risk: a meta-analysis involving 10,184 cases and 12,911 controls Fang FangLei YaoLong Yu Epidemiology 25 December 2009 Pages: 267 - 271
Transforming growth factor-β1 polymorphisms and breast cancer risk: a meta-analysis based on 27 case–control studies Xiaowei QiFan ZhangJun Jiang Epidemiology 23 March 2010 Pages: 273 - 279
Pooled analysis indicates that the GSTT1 deletion, GSTM1 deletion, and GSTP1 Ile105Val polymorphisms do not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers Amanda B. SpurdlePaul FaheyGeorgia Chenevix-Trench Brief Report 18 November 2009 Pages: 281 - 285
High-throughput resequencing in the diagnosis of BRCA1/2 mutations using oligonucleotide resequencing microarrays Christopher SchroederFanny StutzmannMichael Bonin Brief Report 26 November 2009 Pages: 287 - 297
PALB2 mutations in male breast cancer: a population-based study in Central Italy Valentina SilvestriPiera RizzoloLaura Ottini Letter to the Editor 24 February 2010 Pages: 299 - 301
PALB2 mutations 1592delT and 229delT are not present in Korean breast cancer patients negative for BRCA1 and BRCA2 mutations Jin Ho KimDoo Ho ChoiBruce G. Haffty Letter to the Editor 06 March 2010 Pages: 303 - 306
